β-catenin-IRP2-primed iron availability to mitochondrial metabolism is druggable for active β-catenin-mediated cancer

BACKGROUND: Although β-catenin signaling cascade is frequently altered in human cancers, targeting this pathway has not been approved for cancer treatment. METHODS: High-throughput screening of an FDA-approved drug library was conducted to identify therapeutics that selectively inhibited the cells w...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yuting, Yang, Shuhui, Han, Luyang, Shang, Kezhuo, Zhang, Baohui, Gai, Xiaochen, Deng, Weiwei, Liu, Fangming, Zhang, Hongbing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9879242/
https://www.ncbi.nlm.nih.gov/pubmed/36703130
http://dx.doi.org/10.1186/s12967-023-03914-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9879242/
https://www.ncbi.nlm.nih.gov/pubmed/36703130
http://dx.doi.org/10.1186/s12967-023-03914-0

Ejemplares similares